Hemogenyx Pharmaceuticals Plc Banner Image

Hemogenyx Pharmaceuticals Plc

  • Ticker HEMO
    Exchange LSE More
  • Industry Biotechnology More
  • Sector Healthcare More
Hemogenyx Pharmaceuticals Plc Logo Image
  • 1-10 Employees
  • Based in London, England
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. The company is developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subsetMore of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; CAR-T therapy, a chimeric antigen receptor T-cells for use in immunotherapy, as well as for R/R AML; and Human Postnatal Hemogenic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. Hemogenyx Pharmaceuticals Plc has a collaboration with GlobalCo. The company was incorporated in 2013 and is headquartered in London, the United Kingdom.
4.7 / 5.0 (129)

Hemogenyx Pharmaceuticals Plc reports have an aggregate usefulness score of 4.7 based on 129 reviews.

Hemogenyx Pharmaceuticals Plc

Most Recent Annual Report

Hemogenyx Pharmaceuticals Plc
MOST RECENT 2022 Annual Report

Older/Archived Annual Reports

Hemogenyx Pharmaceuticals Plc Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!